Chapter 726: [Science innovation board ready to come out]

At this time, Lu Zhengyang introduced their technological achievements in an orderly manner: "After more than a year of research and development, this nano-robot finally came out. I think it is necessary to say that this type of nano-robot can not only be used In addition to serving as a killer weapon that physically kills cancer cells, it can also be used as a vehicle for carrying therapeutic drugs."
"If it is used as the former, the current nanorobot is not mature enough and needs further improvement before clinical trials. However, we have also purchased a set of organ simulators from Huachang Technology for trials."
Lu Zhengyang is also very frank, saying one thing, not fooling people and talking big.
"For now, our experimental progress has not been able to destroy designated cancer cells in the cell population. All cells around this type of nanorobot, whether good or bad, will be indiscriminately committed suicide by it. Spiral attack'."
The people present were also quite astonished when they heard it. This nano-robot is now in a rhythm that is irrespective of the enemy or the enemy. Whether it is a normal cell or a cancer cell, it will be destroyed.
But this characteristic has given some people other ideas. There are all kinds of people at the expo, and there is no shortage of intelligence agencies from various countries.
In the exhibition area where Lu Zhengyang was located, foreign intelligence personnel were onlookers as tourists. After hearing this explanation, the first idea that came to his mind was biochemical weapons.
The characteristics of this nanorobot are enough to kill people from the microscopic scale.
The two co-founders of Lu Zhengyang and Zhao Yu have never thought of using the technology they researched for weaponization. They have always been committed to benefiting mankind. It can be explained that the co-founded company belongs to the medical device industry.
Different positions have led to different results, once again explaining that technology is a double-edged sword.
Lu Zhengyang said:
The organ simulator that we purchased from Huachang Technology will arrive soon. Next, our team will conduct the next stage of microbiological experiment testing and continue to improve this nano-robot. I believe its future Applications can truly bring the gospel to mankind."
After the voice fell, there was a warm applause.
Ding Xian did not stay in front of the stage for too long. He whispered to the assistant secretary who was accompanying him. After almost ten minutes, he left the front of the stage and met with Lu Zhengyang behind the scenes of the Hongrui Medical booth.
When he arrived backstage, Ding Xiancai unexpectedly discovered that besides him, many other VCs in the same industry had arrived before him, and smiled and nodded in greeting.
But Ding Xian knew that on the surface they nodded and smiled in doubt, and most of them were scolding each other in their hearts.
In the next half an hour, Lu Zhengyang met and discussed with several major VCs who came to visit. Hongrui Medical has only been established for about three years, but it has already completed the B round of financing before, and without exception, it is from the Blue Coast, Shengfeng Capital does not accept other venture capital institutions.
Because the agreement between Hongrui Medical and Azure Coast and Shengfeng Capital is that if the company wants to conduct external financing, Azure Coast and Shengfeng Capital have priority and exclusive investment. Unless the priority and exclusive investment are waived, other VC institutions will not be able to gain Rui's car.
Therefore, the previous financing was all funded by Luo Sheng's institution, and other VC institutions were helpless, but they did nothing.
However, these VC institutions have been staring at them, and by the next C round of financing, they have already received news that Luo Sheng is going to put other VCs on the car. This is not an exception. Many Côte d’Azur strategic investment departments, Sheng For the potential investment projects that Peak Capital is looking at, the C round used to eat alone, and it has been shared since the C round.
Do this to ensure that you can eat the biggest piece of cake, and at the same time, let some people come in and make a fortune. Of course, there is also the possibility of investment failure, so take the risk together.
However, most investment institutions are very keen, because Luo Sheng has almost no precedent for overturning. As long as he let go, VC will not hesitate to throw money in. Because Luo Sheng is on this table, everyone is at ease. I don't understand the model and future of a company, but as long as Luo Sheng is in the car, the VCs don't think much about it. They will be done as soon as they close their eyes. They can basically get a bite of meat with Luo.
About an hour or so, Ding Xian left here, and was quite satisfied when he came out of the backstage, because he also successfully got on the car.
Hongrui Medical’s Series C financing was successfully discussed within this hour. There are 6 venture capital institutions participating in this round of financing, led by Shengfeng Capital. The Series C financing totaled US$75 million, or approximately RMB 500 million.
After the C round of financing, Hongrui Medical is valued at US$1.15 billion. The valuation given by the capital market means that a unicorn-level start-up technology company has been born in the technology industry.
Once the nanorobot developed by Hongrui Medical achieves a major breakthrough, the future prospects are boundless.
Although it seems that the day of success is still quite far away, the technological progress made by the Lu Zhengyang team is visible, which gives investors great confidence, willingness to take greater risks and give Hongrui Medical a higher Valuation and expect it to thrive.
...
Côte d'Azur CEO office.
Luo Sheng stood near the office window and silently overlooked the Expo site below. The location of his office has a very good view. Standing next to the floor-to-ceiling windows, the Expo site has a clear view.
Today is the second day of the exhibition, and there are crowds of people underneath, and it's so busy.
At this time, the office door was knocked several times.
"Come in."
Luo Sheng turned around and looked around, and it was Yao Jianhong who walked in.
"The leaders of the China Securities Regulatory Commission have gone?" Luo Sheng came from the French window and sat down on the sofa in the rest area of ​​the office.
Yao Jianhong, who was sitting across from him, nodded: "Well, let's go, basically it's settled."
The leaders of the China Securities Regulatory Commission came to the Côte d’Azur in person this time for the purpose of opening the board of science and technology innovation board, which is very important next year.
The Sci-tech Innovation Board is a newly established board independent of the existing main board market of Big A, and a pilot registration system is conducted in this board.
There is no doubt that this is a very important new sector that the country attaches great importance to, and its market positioning is the innovation-driven and technology-powered strategy.
To open the Sci-tech Innovation Board, it will definitely require a number of high-quality innovative companies to be listed on the Sci-Tech Innovation Board, and most of the new startups that can be called the brand are not listed on the Blue Coast.
It's really a lot.
The Sci-tech Innovation Board would not be representative if there were no technology companies listed on the Blue Coast.
In fact, the Securities Regulatory Commission has repeatedly studied the possibility of whether the Blue Coast company can be listed on the Science and Technology Innovation Board, and directly chose to give up after the study.
First, whether the Côte d'Azur is listed or not has to lobby Luo Sheng, and the China Securities Regulatory Commission also knows that Luo Sheng will not let the company go public, including Huawei, because there is really no shortage of money and no margin financing is required.
And another reason that cannot be ignored is equally important. If the current volume of the Côte d'Azur is opened on the Science and Technology Innovation Board, it is really incredible.
The entire sector will have to be broken by this big guy. If the Côte d'Azur goes public, you don't have to think about it. Its valuation must start at 20 trillion yuan, and excluding exchange rate changes, it will start at 3 trillion US dollars.
The blood of the entire big A stock market has to be drained by this company. Maybe it may not be too much for two or three years, so the CSRC gave up.
The Big A motherboard already has the super giant, the Blue Pure Electric Automobile Company, with a current market value of 11.47 trillion.
The conclusion is that the current big A is not enough to carry two super giants at the same time.
However, the opening of the Sci-tech Innovation Board has already set the tone, but the outside world does not know about this. The specific opening time has not been announced. Only a handful of institutions have been notified. The Cote d'Azur is one of them.
Obviously, the sci-tech innovation board cannot be opened without high-quality stocks.
"The first batch of listed companies on the Sci-tech Innovation Board is set to be 28. The China Securities Regulatory Commission hopes that we can provide 10 high-quality stocks as weighted stocks to open the market on the Sci-Tech Innovation Board. There are 35 companies selected from the company, Mr. Luo, please take a look."
Yao Jianhong put the documents he brought on the table and pushed it to Luo Sheng, who opened the list on the list.
Lao Yao has selected 35 companies, but the 10 companies that are finally listed on the Sci-tech Innovation Board are handed over to Luo Sheng to make a decision.
The first to bear the brunt is Xiongxin Electronics, the largest chip foundry manufacturer in China, and the highest valuation among the first 28 listed companies on the Sci-tech Innovation Board. The valuation given is 1.45 trillion yuan, excluding exchange rate changes. At 215 billion U.S. dollars, this valuation is only less than 20 billion U.S. dollars away from the current market value of the performance leader Liji.
Once Xiongxin Electronics is listed on the Sci-tech Innovation Board, it will undoubtedly become the absolute leading stock, far ahead of other listed companies on the Sci-Tech Innovation Board.
Even if it is placed in the entire Big A, its market value ranking is also ranked fifth, and the newly opened Sci-tech Innovation Board really needs such a pin, a proper card.
"Xiongxin Electronics...hmm."
Luo Sheng looked at it for a while, then took a pen and checked the company’s list, which meant that he agreed that Xiongxin Electronics should be listed on the Sci-tech Innovation Board. .
The second is the startup company with the most potential for EDA software development in China-Jingchuang Technology, with a valuation of 57 billion yuan.
The third is in the field of medical devices. Huachang Technology, which was founded by Junhui Cao and focused on the development of organ simulators, is now profitable. UU Kanshu www.uukanshu.com has business contacts with major global biomedical research and development giants , The valuation given is 320 billion yuan.
The fourth one is Borch Technology, which develops human bionic prostheses. The company founded by Chen Xin after the 1990s has also achieved profitability, with a valuation of 178 billion yuan.
"Just these 10 companies, report them to the Securities Regulatory Commission."
About ten minutes later, Luo Sheng selected 10 of the 35 companies selected by Lao Yao to log on to the Sci-tech Innovation Board and return the documents to him.
"Okay, I will deal with it now." Yao Jianhong picked up the file and left Luo Sheng's office.
There is no doubt that these 10 companies that are about to land on the Sci-tech Innovation Board are the best targets for value investment, and they are definitely the most popular stocks for price investment.
The industries in which these 10 companies are located are the chip semiconductor and medical device industries. It is certain that the trend of the technology and medical industry in 2019 next year will definitely usher in a sector bull market.
...